Harris v. Pfizer Inc

Background

Roslyn Harris and Mary Allen brought a proposed class action against Pfizer after Pfizer recalled Chantix because it contained N-nitroso-varenicline, a nitrosamine chemical classified as possibly carcinogenic. The Food and Drug Administration announced a recall of nine lots on July 2, 2021; Pfizer later expanded the recall to twelve lots and then to all lots at the consumer level. The plaintiffs bought recalled Chantix in New Jersey and New York, paid copays, and consumed at least some of the medication.

The plaintiffs did not allege that Chantix caused them physical or emotional harm. They sought damages only for economic loss, alleging that they would not have purchased the medication if they had known about the contamination and that the product was therefore worthless. Their amended complaint asserted claims for breach of express warranty, breach of the implied warranty of merchantability, violation of the New Jersey Consumer Fraud Act, unjust enrichment, fraud, negligent misrepresentation, and violations of New York General Business Law sections 349 and 350.

Pfizer moved to dismiss for lack of standing under Federal Rule of Civil Procedure 12(b)(1) and for failure to state a claim under Rule 12(b)(6). The court exercised jurisdiction under the Class Action Fairness Act. The plaintiffs did not assert a private claim under the Food, Drug, and Cosmetic Act or a products-liability claim based on personal injury.

Standing

The court held that the plaintiffs plausibly alleged an economic injury sufficient for standing. They alleged that Pfizer failed to disclose a serious defect and that they paid more for Chantix than they would have paid with complete information. Pfizer’s argument that the plaintiffs received the full benefit of their bargain concerned the merits of their claims, not whether they could bring them.

Failure to State a Claim

The court dismissed the claims under Rule 12(b)(6), which tests whether a complaint alleges enough facts to make legal relief plausible.

Fraud and omission. The plaintiffs argued that Pfizer misrepresented the product by calling it Chantix and identifying varenicline as its active ingredient. The court ruled that those labels accurately described what the plaintiffs received and did not promise that varenicline was the only biologically active ingredient or that the drug was free of nitrosamines. The complaint also did not plausibly allege that Pfizer knew Chantix was actually contaminated when the plaintiffs bought it. General allegations that nitrosamines had been found in other drugs and that a distributor had been warned of a contamination risk were insufficient to show knowledge of actual contamination or an intent to induce reliance.

The court also rejected the fraudulent-omission theory. The plaintiffs did not allege a special or fiduciary relationship, sufficient knowledge by Pfizer, or a partial statement that became misleading because Pfizer failed to disclose contamination. The New Jersey Consumer Fraud Act claim failed for substantially the same reasons: the complaint did not plausibly allege a misleading statement, knowing concealment, or an intent to defraud.

Negligent misrepresentation. Because the plaintiffs sought only economic damages, the court applied the economic-loss rule and dismissed this claim. It also concluded that the alleged statement that the product was Chantix containing varenicline was not an independent misrepresentation separate from the alleged contractual promise, and that the complaint did not plausibly allege a duty to disclose.

New York advertising and deceptive-practices claims. Mary Allen’s claims under New York General Business Law sections 349 and 350 failed because the complaint did not identify a materially misleading statement. The court ruled that consumers’ incorrect inference that the product contained no nitrosamine was not enough; the inference had to be reasonably traceable to a misleading statement by Pfizer. The omission theory also failed because the complaint did not plausibly allege that Pfizer knew about the contamination when the plaintiffs purchased Chantix.

Express warranty. The court ruled that the plaintiffs did not identify an express promise that Chantix was completely safe or free from nitrosamines. Calling the product Chantix and identifying varenicline as its active ingredient did not create such a warranty. The court further stated that, because Chantix is itself a brand-name drug, its name did not warrant that it was chemically identical to another product.

Implied warranty of merchantability. Allen’s claim also failed because she bought Chantix from a pharmacy, not Pfizer, and did not allege personal injury; under New York law, that claim therefore lacked the required direct contractual relationship. Both plaintiffs’ claims failed for an additional reason: they did not plausibly allege that Chantix was unfit for its ordinary purpose of helping consumers quit smoking. The complaint did not allege that the contamination harmed them or placed them at significant risk, and the Food and Drug Administration had stated that there was no immediate risk to patients taking Chantix.

Unjust enrichment. The court dismissed this claim because the plaintiffs did not explain how it differed from their contract and tort claims. Under the governing law, unjust enrichment is not a substitute or catchall claim when it duplicates conventional claims.

Disposition

Judge Denise Cote granted Pfizer’s December 1 motion to dismiss. The Clerk of Court was directed to enter judgment for the defendants and close the case. The opinion did not state that the dismissal was with or without prejudice.